

Resource Summary Report

Generated by [SPARC SAWG](#) on Sep 5, 2026

Medical Dictionary for Regulatory Activities

RRID:SCR_003751

Type: Tool

Proper Citation

Medical Dictionary for Regulatory Activities (RRID:SCR_003751)

Resource Information

URL: <http://purl.bioontology.org/ontology/MEDDRA>

Proper Citation: Medical Dictionary for Regulatory Activities (RRID:SCR_003751)

Description: Ontology of Medical Dictionary for Regulatory Activities Terminology (MedDRA)

Abbreviations: MEDDRA

Resource Type: controlled vocabulary, data or information resource, ontology

Keywords: umls

Resource Name: Medical Dictionary for Regulatory Activities

Resource ID: SCR_003751

Alternate IDs: nlx_157471

Record Creation Time: 20220129T080220+0000

Record Last Update: 20260903T234630+0000

Ratings and Alerts

No rating or validation information has been found for Medical Dictionary for Regulatory Activities.

No alerts have been found for Medical Dictionary for Regulatory Activities.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Rosen EY, et al. (2026) Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1411.

Hamid O, et al. (2025) First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(19), 4089.

Siu LL, et al. (2025) A First-in-Human Study of ATM Inhibitor Lartisertib as Monotherapy in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(21), 4429.

Xu L, et al. (2025) Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS). European journal of medical research, 31(1), 93.